Humacyte (HUMA) vs LENZ Therapeutics (LENZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Humacyte (HUMA) has outperformed LENZ Therapeutics (LENZ) over the past year, losing 71.3% versus a loss of 92.3%. Over five years, HUMA leads with a -95.4% price change compared with -96.0% for LENZ. Humacyte is the larger company by market cap ($131.2 million vs $113.7 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HUMA | LENZ |
|---|---|---|
| Share price | $0.4723 | $3.62 |
| Market cap | $131.20M | $113.74M |
| 1-day change | -1.19% | -4.49% |
| YTD return | -50.85% | -77.38% |
| 1-year return | -71.29% | -92.29% |
| 5-year return | -95.38% | -95.95% |
| EPS (TTM) | $-0.51 | $-4.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.90 | $49.25 |
| 52-week low | $0.46 | $3.46 |
| Distance from 52-week high | -75.08% | -92.65% |
| Average volume | 6.35M | 838.15K |
| Shares outstanding | 277.80M | 31.42M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HUMA has outperformed LENZ by 21.0 percentage points over the past year.
HUMA vs LENZ FAQ
Which is bigger, Humacyte or LENZ Therapeutics?
Humacyte (HUMA) is larger, with a market capitalization of $131.20M compared with $113.74M for LENZ Therapeutics (LENZ).
Which stock has performed better over the past year, HUMA or LENZ?
HUMA returned -71.29% over the past 12 months, compared with -92.29% for LENZ (price return, excluding dividends). Past performance does not predict future results.
Are Humacyte and LENZ Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.